JP2021016375A - Aerobic motor function improver, food composition for aerobic motor function improvement, and pharmaceutical composition for aerobic motor function improvement - Google Patents

Abstract

To provide an aerobic motor function improver that can be blended with foods to pharmaceuticals and has high versatility, and poses only a low risk of side effect even when taken continuously.SOLUTION: The present invention provides an aerobic motor function improver containing medium chain fatty acid as an active ingredient; a food composition for aerobic motor function improvement containing the aerobic motor function improver; and a pharmaceutical composition for aerobic motor function improvement containing the aerobic motor function improver. The aerobic motor function improver may be ingested by a person who does not have a habit of exercise.SELECTED DRAWING: None

Description

The present invention relates to an aerobic motor function improving agent, a food composition for improving aerobic motor function, and a pharmaceutical composition for improving aerobic motor function.

In recent years, the increase in energy intake due to the improvement of eating habits and westernization, and the decrease in the amount of exercise due to the development of transportation means and the increase in desk work have been added, which may cause various lifestyle-related diseases. It has been clarified and has become a social problem from the viewpoint of maintaining and improving the health of the people.
As prevention and correction of lifestyle-related diseases, it has been proposed to work on both a well-balanced diet and moderate exercise, but for exercise, incorporating aerobic exercise such as walking, jogging, and swimming is obesity. It is expected to lead to prevention and prevention of metabolic syndrome.

However, people who do not exercise on a regular basis and tend to sit down (non-exercise habits) have low energy metabolism efficiency, so it takes a long time to connect aerobic exercise to the prevention of obesity and metabolic syndrome. Therefore, it is difficult for non-exercise habits to realize the effect of exercise on the prevention of obesity and metabolic syndrome, which is consistent with the current situation where the proportion of exercise habits does not increase.
In addition, exercise habits can perform aerobic exercise with high exercise intensity, but non-exercise habits exercise with high intensity is likely to lead to an increase in blood pressure and injury, and it is difficult to do it safely. It has been pointed out that it is not recommended.

Therefore, especially for non-exercise habits, ingestion of foods, medicines, etc. can improve the exercise function during aerobic exercise, increase the exercise intensity that can be performed, and improve the efficiency of the time required for aerobic exercise. It is also important from the viewpoint of prevention and correction of lifestyle-related diseases. In addition, by increasing the viable exercise intensity of aerobic exercise, the types of exercise that can be selected are expanded, and it becomes possible to more freely select the type of exercise.

So far, regarding the exercise function due to the intake of medium-chain fatty acid triglyceride, the function evaluation when exercising by determining the exercise intensity based on the maximum oxygen uptake (Non-Patent Document 1), exercise based on the blood lactate concentration during exercise. Functional evaluation (Non-Patent Document 2) and the like when exercising by determining intensity have been reported, but no study has been conducted to evaluate the tolerable upper limit of aerobic motor function.
In addition, as a method for enhancing the effect of aerobic exercise, ingestion of foods and drinks containing a Reishi component (Patent Document 1) and a composition containing a protein in royal jelly as an active ingredient (Patent Document 2) have been reported. However, concerns about side effects during continuous ingestion and the versatility of the ingestion form have not been fully investigated.

Journal of Nutritional Science and Vitaminology, 55, 120-125 (2009) Journal of Nutrition, 125, 531-539 (1995)

Japanese Unexamined Patent Publication No. 5-123135 Japanese Unexamined Patent Publication No. 2001-172195

An object of the present invention is to provide an aerobic motor function improving agent which can be blended from foods to pharmaceuticals, has high versatility, and has little concern about side effects even when continuously ingested.

The present inventors have found that medium-chain fatty acids unexpectedly improve motor function during aerobic exercise, and have completed the present invention. Specifically, the present invention provides:
(1) An aerobic motor function improving agent containing a medium-chain fatty acid as an active ingredient.
(2) The aerobic motor function improving agent according to (1), which is intended for non-exercise habits.
(3) The aerobic motor function improving agent according to (1) or (2), wherein the aerobic motor function improving agent has an action of improving oxygen uptake ability.
(4) A food composition for improving aerobic motor function, which comprises the aerobic motor function improving agent according to any one of (1) to (3).
(5) A pharmaceutical composition for improving aerobic motor function, which comprises the aerobic motor function improving agent according to any one of (1) to (3).
(6) Any of (1) to (3), wherein the non-exercise habitual person is a person other than a person who exercises for 30 minutes or more at a time twice a week or more and continues for one year or more. The aerobic motor function improving agent according to one.
(7) The aerobic exercise function improving agent according to any one of (1) to (3), wherein the aerobic exercise is a physical activity of 3 mets or more.

According to the present invention, there is provided an aerobic motor function improving agent that can be blended from foods to pharmaceuticals, has high versatility, and has little concern about side effects even when continuously ingested.

Hereinafter, embodiments of the present invention will be described in detail, but the present invention is not particularly limited thereto.

[Aerobic motor function improver]
The aerobic motor function improving agent of the present invention contains a medium-chain fatty acid as an active ingredient. Hereinafter, "medium chain fatty acid" is also referred to as "MCFA". "Containing a medium-chain fatty acid as an active ingredient" means that at least a medium-chain fatty acid is contained as a physiologically active substance contained in the aerobic motor function improving agent of the present invention.

The composition of the aerobic motor function improving agent of the present invention will be described in detail below.
<Medium chain fatty acid (MCFA)>
MCFA is a linear saturated fatty acid having 6 to 12 carbon atoms, and is a fat and oil component contained in ordinary foods and the like (for example, edible fats and oils, dairy products, etc.). From the viewpoint that a safer aerobic motor function improving agent can be easily obtained, MCFA is preferably a linearly saturated fatty acid having 8 to 12 carbon atoms, and linearly saturated with 8 and / or 10 carbon atoms. It is more preferably a fatty acid. Specific MCFAs include caproic acid (n-hexanoic acid), caprylic acid (n-octanoic acid), capric acid (n-decanoic acid), and lauric acid.
MCFA is obtained, for example, by hydrolyzing palm kernel oil or coconut oil and then refining it. In addition, commercially available products and reagents can be used as MCFA.

The form of MCFA contained in the aerobic motor function improving agent is not particularly limited, and may be a medium-chain fatty acid itself, or a fatty acid precursor (for example, a salt or an ester) that is converted into a medium-chain fatty acid in vivo. (Acylglycerol, etc. described later)), or a mixture thereof.
MCFA is usually ingested in the body in the form of fatty acid precursors, more specifically acylglycerol in which MCFA and glycerin are ester-bonded. From the viewpoint of higher safety and the like, the form of MCFA contained in the aerobic motor function improving agent of the present invention is preferably acylglycerol.

Acylglycerol has a structure in which a fatty acid and glycerin are ester-bonded, and exists in one of three forms (monoacylglycerol, diacylglycerol, and triacylglycerol) depending on the number of fatty acids bound to glycerin. To do. The acylglycerol in the present invention may be in any of the above three forms, but at least one of the constituent fatty acids is MCFA. As the acylglycerol in the present invention, triacylglycerol (hereinafter, also referred to as triglyceride) is preferable from the viewpoint that it can be blended from foods to pharmaceuticals and has high versatility. Further, in the present invention, the fatty acids constituting diacylglycerol and triacylglycerol may be of the same type or different types. In the case of acylglycerol composed of different types of fatty acids, the binding position of each fatty acid to glycerin is not particularly limited. Further, as a constituent fatty acid of acylglycerol, a fatty acid other than MCFA (for example, a long chain fatty acid having 14 to 22 carbon atoms) may be contained.

The lower limit of the proportion of MCFA in the total constituent fatty acids of acylglycerol in the present invention is preferably 10% by mass or more, more preferably 40% by mass or more, and more preferably 80% by mass or more. The upper limit is preferably 100% by mass or less. Within the above range, the aerobic motor function improving effect of MCFA can be more effectively exerted. When the aerobic motor function improving agent of the present invention contains an acylglycerol containing MCFA as a constituent fatty acid, an acylglycerol containing no MCFA may be further added to the constituent fatty acid. In such a case, the ratio of MCFA in the total constituent fatty acids to the total acylglycerol blended in the aerobic motor function improving agent may be within the above range.

The method for producing acylglycerol is not particularly limited, but for example, an esterification reaction using medium-chain fatty acid or long-chain fatty acid derived from coconut oil or palm kernel oil and glycerin, or medium-chain fatty acid alkyl or long-chain fatty acid alkyl. It can be obtained by conducting an ester exchange reaction using glycerin and glycerin as raw materials. The conditions of the esterification reaction are not particularly limited, and the reaction may be carried out under pressure without a catalyst and without a solvent, or may be carried out using a catalyst or a solvent. The MLCT can also be obtained by transesterifying MCT with fats and oils other than MCT. The method for transesterification is not particularly limited, and a usual method such as chemical transesterification using sodium methoxide as a catalyst or enzymatic transesterification using a lipase preparation as a catalyst may be used.

From the viewpoint that a safer aerobic motor function improving agent can be easily obtained, the acylglycerol in the present invention includes MCFA and long chain fatty acids (for example, linear long chain fatty acids having 14 to 22 carbon atoms) as constituent fatty acids. ) And a triglyceride, that is, a medium-long chain fatty acid triglyceride is preferable. As the acylglycerol in the present invention, a triglyceride in which all the constituent fatty acids are MCFA, that is, a medium-chain fatty acid triglyceride is particularly preferable. Hereinafter, "medium-chain fatty acid triglyceride" is also referred to as "MLCT", and "medium-chain fatty acid triglyceride" is also referred to as "MCT". The form of MCFA contained in the oily aerobic motor function improving agent of the present invention preferably contains MLCT and / or MCT, and more preferably contains only MCT. The aerobic motor function improving agent of the present invention particularly preferably comprises MCT.

The aerobic motor function improving agent of the present invention may consist of MCFA (MCFA itself, fatty acid precursor of MCFA (MLCT, MCT, etc.), or a mixture thereof), but together with MCFA, other than MCFA. It may contain an ingredient.
When the aerobic motor function improving agent of the present invention contains a component other than MCFA, MCFA (fatty acid precursor of MCFA (MLCT, MCT, etc.) or a mixture thereof) contained in the aerobic motor function improving agent or a mixture thereof. In this case, the lower limit of the blending amount (converted to the amount of MCFA) is preferably 33% by mass or more, more preferably 50% by mass or more, still more preferably 70% by mass or more with respect to the aerobic motor function improving agent. Is. The upper limit is preferably 99% by mass or less, more preferably 95% by mass or less, and even more preferably 90% by mass or less. Within the above range, the aerobic motor function improving effect of MCFA can be more effectively exerted.

The components other than MCFA contained in the aerobic motor function improving agent of the present invention are not particularly limited as long as they do not inhibit the action of MCFA. Examples of such a component include an active ingredient (Ganoderma lucidum component and the like) known to have an aerobic motor function improving effect, an antioxidant, an emulsifier and the like. The type and blending amount of these components can be appropriately set according to the effect to be obtained.

The content of MCFA contained in the aerobic motor function improving agent of the present invention is based on the "Standard Fatty Acid Analysis Test Method 2.4.2.2-2013 Fatty Acid Composition (Capillary Gas Chromatograph Method)" established by the Japan Oil Chemists' Society. Further, as a method for confirming and quantifying molecular species such as MCT and MLCT in the triglyceride contained in the aerobic motor function improving agent of the present invention, for example, a gas chromatograph method (JAOCS, vol70, 11, 1111) can be specified. A method using -1114 (1993) can be mentioned.

<Aerobic motor function improving effect>
The aerobic motor function improving agent of the present invention has an action of improving the motor function during aerobic exercise in humans. The aerobic motor function improving agent of the present invention can be preferably used to improve the motor function of a non-exercise habitual person during aerobic exercise. By using the aerobic exercise function improving agent of the present invention, the execution time of aerobic exercise can be extended as compared with the conventional case, and aerobic exercise can be performed with high exercise intensity. , It is easy to feel the effect of exercise on the prevention of obesity and metabolic syndrome.
Especially for non-exercise habits, it is not necessary to excessively increase the exercise intensity, and there is an advantage that the risk of an increase in blood pressure and injury can be reduced.

In the present invention, "improvement of aerobic exercise function" means that the execution time of aerobic exercise is extended and / or compared with the state before the effect of the aerobic exercise function improving agent of the present invention is obtained. Refers to an increase in viable exercise intensity. In addition, the extension of the execution time of the aerobic exercise and / or the increase in the exercise intensity that can be performed is preferably accompanied by the effect of improving the oxygen uptake capacity.
Here, "aerobic exercise" is exercise with a light or moderate load that can be continued for a long time by aerobic metabolism. And, it is clearly distinguished from anaerobic exercise in which a large amount of lactic acid is generated from non-aerobic metabolism by generating a large force in a short time in response to a high-intensity exercise load.

In the present invention, as an index for confirming the above-mentioned improvement in aerobic motor function, attention is paid to the ventilation threshold (VT, hereinafter also referred to as VT). Here, the VT, the aerobic exercise intensity, the Yuku increasing the exercise intensity gradually, eventually than the increase of the oxygen uptake (VO _2), ventilation and carbon dioxide emissions (VCO ₂₎ It refers to the threshold at which a significant increase is found (the turning point for anaerobic exercise). Therefore, in the above, the extension of the execution time of aerobic exercise can be confirmed as an event in which the VT is extended.
In addition, when the oxygen uptake capacity is improved, VO ₂ is increased and the oxygen supply to active muscles during exercise is increased. Then, it is considered that the energy acquisition from the energy supply system by oxidative phosphorylation increases, so that the increase of VCO ₂ is delayed, and as a result, the VT is extended.

[Non-exercise habit]
The non-exercise habitual person of the present invention is a person who does not exercise on a daily basis, specifically, based on the definition of an exercise habitual person of the National Nutrition Survey, "exercise for 30 minutes or more once, twice a week. Refers to persons other than those who have carried out the above and have continued for one year or more. In addition, the exercise of the present invention refers to physical activity of 3 METs or more. Mets defines the intensity as a multiple of the metabolic amount at rest, with 1 Mets as the amount of metabolism. The energy consumption per hour (Kcal / hour) of 1 MET is almost the same as the numerical value (kg) of the body weight of the subject, and 1 MET of a person weighing 60 kg corresponds to 60 Kcal / hour. Specific examples include walking (4.3 METs), cycling (8.0 METs, 20 km / hour), swimming (10.0 METs, fast crawl, 69 m / min) and the like. The "Physical Activity Standards for Health Promotion 2013" recommends that 3 to 6 METs of physical activity be performed 150 minutes a week internationally.
The exercise of the present invention may be combined with the anaerobic exercise, but it is preferable that the exercise time of the exercise of the present invention is longer than the exercise time of the anaerobic exercise.

[Food composition for improving aerobic motor function]
The aerobic motor function improving agent of the present invention can be applied for the production of a food composition for improving aerobic motor function. MCFA, which is the active ingredient of the aerobic motor function improving agent of the present invention, not only has less concern about side effects, but also does not easily impair the flavor and palatability of foods. Therefore, the food composition for improving aerobic motor function containing the aerobic motor function improving agent of the present invention (hereinafter, also referred to as "food composition of the present invention") can be preferably used as a food that is easy to eat.

Examples of the form of the food composition of the present invention include supplements and general foods.
The form of the supplement is not particularly limited and may be either a solid preparation or a liquid preparation. For example, tablets, coated tablets, capsules, granules, powders, powders, sustained-release preparations, suspensions, emulsions, oral solutions, sugar-coated tablets, pills, fine granules, syrups, elixirs, etc. Can be mentioned.

The form of general food is not particularly limited, and for example, bread / confectionery (bread, cake, cookie, biscuits, donuts, muffins, scones, chocolate, snack confectionery, whipped cream, ice cream, etc.), beverages (fruit juice beverage, nutrition). Drinks, sports drinks, etc.), soups, seasoned processed foods (dressing, sauces, mayonnaise, butter, margarine, prepared margarine, etc.), fat spreads, shortening, bakery mix, roasted oil, frying oil, frying food, processed meat products, Examples include frozen foods, fried foods, noodles, retort foods, liquid foods, swallowing foods and the like.

When the aerobic motor function improver of the present invention is used for the production of general foods, it is added to the raw material in the form of MLCT and / or MCT (more preferably MCT), or the fat and oil of the raw material is added to MLCT and / or. Alternatively, it is preferable to replace it with MCT (more preferably MCT).

The intake amount of the food composition of the present invention can be appropriately set according to the purpose of intake (prevention, etc.), the period of intake, and other conditions (for example, the symptom, age, and weight of the eater).

The intake amount of the food composition of the present invention can be set to preferably 0.02 g / kg body weight / day or more, more preferably 0.08 g / kg body weight / day or more in terms of the lower limit value in terms of the amount of MCFA. .. The upper limit can be set to 0.70 g / kg body weight / day or less, more preferably 0.45 g / kg body weight / day or less in terms of the amount of MCFA.

The intake amount of the food composition of the present invention can be set to preferably 0.03 g / kg body weight / day or more, more preferably 0.09 g / kg body weight / day or more in terms of the amount of MCT. .. The upper limit can be set to 1.00 g / kg body weight / day or less, more preferably 0.50 g / kg body weight / day or less in terms of the amount of MCT.

The food composition of the present invention is suitable for continuous ingestion. The ingestion period is not particularly limited, but can be set to, for example, 7 days or more, preferably 14 days or more. Ingestion may be performed every few hours during the above period, or may be performed at intervals (for example, one to several days).

[Pharmaceutical composition for improving aerobic motor function]
The aerobic motor function improving agent of the present invention can be applied for the production of a pharmaceutical composition for improving aerobic motor function. The pharmaceutical composition for improving aerobic motor function containing the aerobic motor function improving agent of the present invention (hereinafter, also referred to as “pharmaceutical composition of the present invention”) has less concern about side effects and is suitable for continuous administration. It can be preferably used as a pharmaceutical product.

The form of the pharmaceutical composition of the present invention is not particularly limited, but it can be prepared as either a pharmaceutical composition for oral administration or a pharmaceutical composition for parenteral administration. Examples of the form of the pharmaceutical composition for oral administration include preparations such as capsules, tablets, pills, powders, fine granules, granules, liquids, and syrups. Examples of the form of the pharmaceutical composition for parenteral administration include preparations such as injections and infusions. From the viewpoint of easy continuous administration, the pharmaceutical composition of the present invention is preferably a pharmaceutical composition for oral administration.

The pharmaceutical composition of the present invention is preferably a composition containing the aerobic motor function improving agent of the present invention and additives that are pharmacologically and pharmaceutically acceptable. As a "pharmacologically and pharmaceutically acceptable additive", a substance that is usually used as an excipient in the pharmaceutical field and does not react with the active ingredient contained in the aerobic motor function improving agent of the present invention is used. Can be used.

The dose of the pharmaceutical composition of the present invention can be appropriately set according to the purpose of administration (prevention or treatment), administration method, administration period, and other conditions (for example, patient's symptoms, age, body weight).
In the case of oral administration, the lower limit of the dose of the pharmaceutical composition of the present invention is preferably 0.02 g / kg body weight / day or more, more preferably 0.08 g / kg body weight / day in terms of the amount of MCFA. Can be set to more than a day. The upper limit can be set to 0.70 g / kg body weight / day or less, more preferably 0.45 g / kg body weight / day or less in terms of the amount of MCFA.

In the case of oral administration, the lower limit of the dose of the pharmaceutical composition of the present invention is preferably 0.03 g / kg body weight / day or more, more preferably 0.09 g / kg body weight / day in terms of the amount of MCT. Can be set to more than a day. The upper limit can be set to 1.00 g / kg body weight / day or less, more preferably 0.50 g / kg body weight / day or less in terms of the amount of MCT.

In the case of parenteral administration, the lower limit of the dose of the pharmaceutical composition of the present invention is preferably 0.026 g / kg body weight / day or more, more preferably 0.09 g / kg body weight in terms of the amount of MCFA. Can be set to / day or more. The upper limit can be set to 0.72 g / kg body weight / day or less, more preferably 0.56 g / kg body weight / day or less in terms of the amount of MCFA.

In the case of parenteral administration, the lower limit of the dose of the pharmaceutical composition of the present invention is preferably 0.029 g / kg body weight / day or more, more preferably 0.10 g / kg body weight in terms of the amount of MCT. Can be set to / day or more. The upper limit can be set to 0.80 g / kg body weight / day or less, more preferably 0.60 g / kg body weight / day or less in terms of the amount of MCT. In the case of parenteral administration, it is preferable to administer the above dose over several hours (for example, over 4 to 8 hours).

Since the pharmaceutical composition of the present invention is less likely to cause side effects and is less likely to interact with general active ingredients, existing therapeutic agents for lifestyle-related diseases (hypertension, diabetes, dyslipidemia, etc.) and the like are already available. It may be used in combination with a drug.

The pharmaceutical composition of the present invention is suitable for continuous administration because there is little concern about side effects. The administration period is not particularly limited, but can be set to, for example, 7 days or more, preferably 14 days or more. Administration may be performed every few hours during the above period, or may be administered at intervals (for example, one to several days).

Hereinafter, the present invention will be described in more detail based on Examples, but the present invention is not limited to these Examples.

[Confirmation of aerobic motor function improvement effect for non-exercise habits]
(1) Test method By a randomized double-blind crossover test, the elapsed time (sec) from the start of exercise to the time of VT and the output power at the time of VT when the test meal was continuously ingested and the exercise load test was performed. (W), oxygen intake (ml / min) at the time of VT, ventilation volume (ml / ml) per CO ₂ excretion at the time of VT, and Mets (METs) at the time of VT were measured.
That is, the elapsed time (sec) from the start of exercise to the VT time point is the time during which aerobic exercise is possible, and the output power (W) at the VT time point and the Mets (METs) at the VT time point can be executed in the aerobic state. The maximum exercise intensity, oxygen uptake (ml / min) at VT, oxygen uptake capacity, and ventilation per CO ₂ excretion at VT (ml / ml) were used as indicators of ventilation efficiency.

(2) Production of test foods Test food A (sugar food), test food B (MCT 1 meal), and test food C (MCT 2 meals) having the formulations shown in Table 1 were produced. In the test meal A, all the raw materials were stirred and dissolved in 300 kg of warm water, and the weight was adjusted with warm water so that the total weight was 500 kg. The test meals B and C are prepared by stirring and dissolving raw materials other than MCT and emulsifier in 300 kg of warm water, adding the emulsifier and stirring, then adding MCT and sufficiently stirring, and weighting with warm water so that the total weight is 500 kg. I matched.
After homogenizing the preparations of the test meals A to C prepared above with a homogenizer, 150 g each was sealed in a retort container and retort sterilized (121 ° C., 10 minutes). Table 1 shows the nutritional components per daily intake (300 g).

MCT-1 (the aerobic motor function improving agent of the present invention) in Table 1 is a product manufactured by Nisshin Oillio Group Co., Ltd., and its constituent fatty acids are n-octanoic acid (8 carbon atoms) and n-decanoic acid. (10 carbon atoms), and the mass ratio is n-octanoic acid: n-decanoic acid = 75:25.
MCT-2 (the aerobic motor function improving agent of the present invention) is a product manufactured by Nisshin Oillio Group Co., Ltd., and its constituent fatty acids are n-octanoic acid (8 carbon atoms) and n-decanoic acid (carbon). Equation 10), and the mass ratio is n-octanoic acid: n-decanoic acid = 30:70.

The nutrition facts label in Table 1 is the content (calculated value) per daily intake (2 packets) of the test meal.

(3) Subjects 15 healthy non-exercise men and women (6 men, 9 women, average age 51.4, average BMI 22.7 ± 1.7, "exercise for 30 minutes or more at a time, "Persons who carry out at least twice a week and have lasted for more than one year" are not included).
(4) Test schedule The above subjects were allowed to continuously ingest either test meal A, test meal B, or test meal C for 13 days until the day before the exercise load test, 2 packets a day (300 g in total). .. On the day of the test, one hour before the exercise stress test, two packs of the same test meals as those taken so far were ingested. After the exercise load test, after a two-week washout, the above test schedule was repeated, and data of the exercise load test was collected for each of the three test meals.

(5) Exercise load test 10 minutes before the start of the exercise load test, the subject was placed on a bicycle ergometer, the height of the seat surface and the toe fixture were adjusted, and a mask for exhaled gas and a heart rate monitor clip were attached. The exhaled breath component was measured after resting for a minute. From the start of the exercise test, subjects were allowed to row a bicycle ergometer with a 20 W load for 3 minutes, and every minute thereafter, the load was increased at a rate of 20 W / min for men and 15 W / min for women (ie, every minute). The gradual load was given). The number of revolutions of the pedal was maintained at 50 to 60 revolutions / minute.
When the linearity of carbon dioxide excretion (VCO ₂ ) increase with respect to oxygen uptake (VO ₂ ) increase is broken by performing breath component analysis (breath-by-breath method) for each subject and using the V-slope method. Was VT. After confirming the appearance of VT, the load was reduced to 20 W to cool down, and then the exercise load test was completed.

(6) Evaluation method For each subject, the time from the start of exercise to the VT time point (sec), the output power at the VT time point (W), the oxygen intake at the VT time point (ml / min), and the CO ₂ excretion amount at the VT time point. Regarding the ventilation volume (ml / ml) and the Mets at the time of VT, when the test meal A was ingested (control example), the test meal B was ingested (Example 1), or the test meal C was ingested (Example 2). ) Was calculated, and the intervention effect value was calculated. The results are shown in Table 2. The numerical values are expressed as "mean ± standard deviation".
The elapsed time from the start of exercise to the VT time point (sec), the output power at the VT time point (W), the oxygen intake amount at the VT time point (ml / min), and the ventilation volume per CO ₂ excretion amount at the VT time point (ml). / Ml) was calculated by using a dedicated software for the data continuously collected by the computer.
In addition, Mets was calculated by dividing the exercise metabolic amount for each subject by the resting metabolic amount when the test meal A was ingested (control example). The average METs of all subjects in the exercise test was 4.88 ± 1.46.

In Table 2, "time point of VT" is the elapsed time (sec) from the start of exercise to the time point of VT, "output power" is the output power (W) at the time of VT, and "oxygen intake" is the amount of oxygen intake at the time of VT (ml). / Min) and "ventilation volume" refer to the ventilation volume (ml / ml) per CO ₂ excretion amount at the time of VT.
Statistical analysis was performed by multiple comparisons to compare the control example with the example. The Bartlett's test was used to test the assumption of homoscedasticity, and when the homoscedasticity could be assumed, the Dunnett method was used, and when the assumption was rejected, the Steel method was used to test the significance of the control example. A risk rate of less than 5% (p <0.05) was considered statistically significant.

From the above results, Examples (Examples 1 and 2) ingesting the test meal B or C containing the aerobic motor function improving agent of the present invention for 14 days ingested the test meal A (sugar diet). Compared with the control example, the elapsed time from the start of exercise to the VT time point, the output power at the VT time point, the oxygen uptake at the VT time point, and the Mets at the VT time point were increased. In addition, the ventilation volume per CO ₂ excretion amount at the time of VT was almost the same between the examples (Examples 1 and 2) and the control example.
Furthermore, regarding the oxygen uptake at VT and Mets at VT, a significant difference was observed in the intervention effect values of Examples 1 and 2, and the elapsed time from the start of exercise to VT and the output power at VT were A significant difference was observed in the intervention effect value of Example 2.

Therefore, the aerobic exercise function improver of the present invention has the effect of improving the time during which aerobic exercise is possible and the maximum exercise intensity that can be performed in the aerobic state, and further, the ventilation efficiency is improved. It is considered to have the effect of improving the oxygen uptake capacity without affecting it.

Claims (5)

An aerobic motor function improver containing medium-chain fatty acids as an active ingredient. The aerobic motor function improving agent according to claim 1, which is intended for non-exercise habits. The aerobic motor function improving agent according to claim 1 or 2, wherein the aerobic motor function improving agent has an action of improving oxygen uptake ability. A food composition for improving aerobic motor function, which comprises the aerobic motor function improving agent according to any one of claims 1 to 3. A pharmaceutical composition for improving aerobic motor function, which comprises the aerobic motor function improving agent according to any one of claims 1 to 3.